Merck wraps up $1.8bn acquisition of Pandion Therapeutics
(adsbygoogle = window.adsbygoogle || []).push({}); Merck has wrapped up its previously announced $1.85 billion acquisition of Massachusetts-based clinical-stage biotech company Pandion Therapeutics. The pharma giant said that it had successfully completed the cash tender offer, via a subsidiary, for all of the outstanding shares of Pandion More...
Sterling Pharma acquires antibody drug conjugate manufacturer ADC Bio
Sterling Pharma Solutions has acquired ADC Biotechnology (ADC Bio), a bioconjugation development services business based in the UK, which specializes in antibody drug conjugates (ADCs). The UK-based contract development More...
Dr. Reddy’s Laboratories launches Sapropterin dihydrochloride powder in US
Dr. Reddy’s Laboratories has launched Sapropterin Dihydrochloride Powder for Oral Solution, 100mg, a generic of BioMarin’s Kuvan (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, approved by More...
Gan & Lee gets EMA orphan drug status for GLR2007 in glioma
Gan & Lee Pharmaceuticals has been granted orphan drug designation for GLR2007 from the European Medicine Agency (EMA) for the treatment of glioma, a type of tumor found in the brain and spinal cord. The Chinese More...
Bioniz Therapeutics gets EC orphan drug status for BNZ-1 for CTCL
Bioniz Therapeutics has secured orphan drug designation for BNZ-1 from the European Commission (EC) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. Previously, BNZ-1 was given More...
Sound Pharmaceuticals gets NIH grant for Covid-19 candidate SPI-1005
Sound Pharmaceuticals has secured a grant of $3.1 million for supporting the evaluation of its COVID-19 treatment candidate SPI-1005 in two phase 2 clinical trials from the National Center for Advancing Translational More...
Grifols phase 3 Covid-19 trial of hyperimmune globulins fails to meet objective
Spanish pharma company Grifols said that the phase 3 ITAC clinical trial assessing hyperimmune globulins as a treatment for patients hospitalized with Covid-19 has failed to meet its primary endpoints. ITAC expands More...
Cellphire Therapeutics raises $15m in Series A funding round
Cellphire Therapeutics, a Maryland-based biotech company focused on the long-term stabilization and storage of platelets, has raised $15 million in a Series A funding round. The financing round was led by Simcah More...
Amgen to acquire Rodeo Therapeutics in $721m worth deal
Amgen has agreed to acquire Rodeo Therapeutics, a Seattle-based biopharma company, in a deal worth up to $721 million. Rodeo Therapeutics is engaged in developing small-molecule therapies designed for promoting More...
Pyxis Oncology raises $152m in Series B round for cancer therapies
Pyxis Oncology, a Boston-based biotech company, has raised $152 million in a Series B financing round co-led by Arix Bioscience and RTW Investments. The company is developing antibody-drug conjugates (ADCs), immunotherapies, More...